9. Quang N N, Miodek A, Cibiel A, et al. Selection of aptamers against whole living cells: from Cell-SELEX to identification of biomarkers. Synthetic Antibodies, 2017, 1575: 253-272.
[2]
10. Dou Xiaoqian, Wang Hua, Zhang Jing, et al. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Int J Nanomedicine, 2018, 13: 763-776.
[3]
11. Hori S I, Herrera A, Rossi J J, et al. Current advances in aptamers for cancer diagnosis and therapy. Cancers (Basel), 2018, 10(1): 9.
[4]
12. Catuogno S, Esposito C L, de Franciscis V. Developing aptamers by cell-based SELEX. Methods in Molecular Biology, 2016, 1380: 33.
14. Wu Qiaoyi, Wang Yuzhe, Wang Hongyao, et al. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells. Analyst, 2018, 143(10): 2267-2275.
[7]
15. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 2013, 63(1): 11-30.
[8]
16. Chen H W, Medley C D, Sefah K, et al. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem, 2008, 3(6): 991-1001.
[9]
17. Kunii T, Ogura S I, Mie Masayasu, et al. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst, 2011, 136(7): 1310-1312.
[10]
18. Zhao Zilong, Xu Li, Shi Xiaoli, et al. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst, 2009, 134(9): 1808-1814.
[11]
19. Zamay G S, Kolovskaya O S, Zamay T N, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Molecular Therapy, 2015, 23(9): 1486-1496.
[12]
20. He Jinfeng, Tan Wei, Ma Jingping. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. Future Oncology, 2017, 13(9): 787-797.
4. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249(4968): 505-510.
[15]
5. Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287): 818-822.
[16]
7. Pang Xuehui, Cui Cheng, Wan Shuo, et al. Bioapplications of Cell-SELEX-generated aptamers in cancer diagnostics, therapeutics, theranostics and biomarker discovery: a comprehensive review. Cancers (Basel), 2018, 10(2): 47.
[17]
8. Shangguan Dihua, Li Ying, Tang Zhiwen, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A, 2006, 103(32): 11838-11843.
[18]
24. Wang Qing, Zhou Chenchen, Yang Xiaohai, et al. Probing interactions between human lung adenocarcinoma A549 cell and its aptamers at single-molecule resolution. Journal of Molecular Recognition, 2014, 27(11): 676-682.
[19]
25. Nabavinia M S, Charbgoo F, Alibolandi M, et al. Comparison of flow cytometry and ELASA for screening of proper candidate aptamer in Cell-SELEX pool. Appl Biochem Biotechnol, 2018, 184(2): 444-452.
[20]
34. Havel L S, Kline E R, Salgueiro A M, et al. Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene, 2015, 34(15): 1979-1990.
[21]
36. Lai Weiyun, Wang Weiya, Chang Y C, et al. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials, 2014, 35(9): 2905-2914.
[22]
2. Gold L, Janjic N, Jarvis T, et al. Aptamers and the RNA world, past and present. Cold Spring Harb Perspect Biol, 2012, 4(3): 829-841.
[23]
3. Mckeague M, Mcconnell E M, Cruz-Toledo J A, et al. Analysis of in vitro aptamer selection parameters. J Mol Evol, 2015, 81(5/6): 150-161.
[24]
6. Chen Chan, Zhou Shan, Cai Yongqiang, et al. Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology. Npj Precision Oncology, 2017, 1(1): 37.
[25]
1. Chen Wanqing, Zheng Rongshou, Baade P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
[26]
21. Zamay G S, Ivanchenko T I, Zamay T N, et al. DNA aptamers for the characterization of histological structure of lung adenocarcinoma. Mol Ther Nucleic Acids, 2017, 6: 150-162.
[27]
22. Wu Chunlei, Liu Jianbo, Zhang Pengfei, et al. A recognition-before-labeling strategy for sensitive detection of lung cancer cells with a quantum dot-aptamer complex. Analyst, 2015, 140(17): 6100-6107.
[28]
26. Sett A, Borthakur B B, Bora U. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas. Clinical & Translational Oncology, 2017, 19(8): 976-988.
[29]
27. Yuan Baoyin, Jiang Xiaochun, Chen Yuanyuan, et al. Metastatic cancer cell and tissue-specific fluorescence imaging using a new DNA aptamet developed by Cell-SELEX. Talanta, 2017, 170: 56-62.
[30]
28. Ott W, Jobst M A, Schoeler C, et al. Single-molecule force spectroscopy on polyproteins and receptor-ligand complexes: The current toolbox. J Struct Biol, 2017, 197(1, SI): 3-12.
[31]
29. Liu Lishang, Lu Xiaoling, Zhao Yongxiang. Aptamer-Based strategies for cancer diagnosis and therapy. J Nanosci Nanotechnol, 2016, 16(7): 6611-6621.
[32]
30. Mackey D, Kelly E, Nooney R. Modelling random antibody adsorption and immunoassay activity. Mathematical Biosciences and Engineering, 2016, 13(6, SI): 1159-1168.
[33]
31. Yin Meili, Li Zhenhua, Liu Zhen, et al. Photosensitizer-incorporated G-quadruplex DNA-functionalized magnetofluorescent nanoparticles for targeted magnetic resonance/fluorescence multimodal imaging and subsequent photodynamic therapy of cancer. Chemical Communications, 2012, 48(52): 6556-6558.
[34]
32. Jin Cheng, Qiu Liping, Li Jin, et al. Cancer biomarker discovery using DNA aptamers. Analyst, 2016, 141(2): 461-466.
35. Almasi F, Gargari S M, Bitaraf F, et al. Development of a single stranded DNA aptamer as a molecular probe for LNCap cells using Cell-SELEX. Avicenna J Med Biotechnol, 2016, 8(3): 104-111.
[37]
37. Perepelyuk M, Sacko K, Thangavel K, et al. Evaluation of MUC1-aptamer functionalized hybrid nanoparticles for targeted delivery of miRNA-29b to non-small cell lung cancer. Molecular Pharmaceutics, 2018, 15(3): 985-993.
[38]
38. Morita Y, Leslie M, Kameyama H, et al. Aptamer therapeutics in cancer: current and future. Cancers (Basel), 2018, 10(3): 80.
[39]
39. Ayatollahi S, Salmasi Z, Hashemi M, et al. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. International Journal of Biochemistry & Cell Biology, 2017, 92: 210-217.
